More weapons in the arsenal against ischemic retinopathy.
Keshet
E
E
Department of Molecular Biology, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.
D000818:Animals; D016228:Endothelial Growth Factors / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D007511:Ischemia / Q000188:drug therapy / Q000378:metabolism; D008222:Lymphokines / Q000378:metabolism*; D009389:Neovascularization, Pathologic; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000502:physiology*; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D012164:Retinal Diseases / Q000188:drug therapy / Q000378:metabolism; D012178:Retinopathy of Prematurity / Q000188:drug therapy / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C496319:NOS2 protein, human; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III